US Stock MarketDetailed Quotes

CRVO CervoMed

Watchlist
  • 8.770
  • -0.610-6.50%
Trading May 7 11:59 ET
76.32MMarket Cap-4.34P/E (TTM)

About CervoMed Company

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

Company Profile

SymbolCRVO
Company NameCervoMed
Listing DateNov 9, 2016
Founded1995
CEODr. John J. Alam, M.D.
MarketNASDAQ
Employees15
Fiscal Year Ends12-31
Address20 Park Plaza,Suite 424
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02216
Phone1-617-744-4400

Company Executives

  • Name
  • Position
  • Salary
  • Dr. John J. Alam, M.D.
  • Chief Executive Officer, President and Director
  • 1.04M
  • Dr. Robert Joseph Cobuzzi, Jr,PhD
  • Chief Operating Officer and Director
  • 813.23K
  • William R. Elder
  • General Counsel, Corporate Secretary, Chief Financial Officer and Principal Accounting Officer
  • 651.75K
  • Kelly Blackburn, M.H.A
  • Executive Vice President, Clinical Development
  • --
  • Dr. Mark De Rosch, PhD
  • Executive Vice President, Regulatory and Government Affairs and Program Management
  • --
  • Dr. Joshua S. Boger,PhD
  • Chairman of the Board
  • 228.21K
  • Dr. Sylvie Gregoire,Pharm.D.
  • Director
  • 114.95K
  • Jane H. Hollingsworth, J.D.
  • Independent Director
  • 132.92K
  • Jeffrey V. Poulton
  • Independent Director
  • 132.42K
  • Frank Zavrl
  • Independent Director
  • 133.92K
  • Dr. Marwan Noel Sabbagh, M.D.
  • Independent Director
  • 116.42K

Market Insights

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.